Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464587) titled 'Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease' on March 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Condition:
Chronic Obstructive Pulmonary Disease
Intervention:
Drug: TQC3721 Suspension for Inhalation
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 2026
Target Sample Size: 800
Countries of Recruitment:
China
To k...